EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Persistence of Antibodies against Measles, Mumps, and Rubella after the Two-Dose MMR Vaccination: A 7-Year Follow-Up Study

Nasiri Sarawanangkoor iD, Nasamon Wanlapakorn iD, Donchida Srimuan, Thaksaporn Thatsanathorn, Thanunrat Thongmee, Yong Poovorawan iD

Vaccines · 05.07.2024 · 12 (7) · 744

DOI: 10.3390/vaccines12070744 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 05.07.2024. Verfasst von Nasiri Sarawanangkoor und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Council of Thailand (NRCT), the Health Systems Research Institute (HSRI), National Research Council of Thailand (NRCT), the Health Systems Research Institute (HSRI), the Ratchadaphisek Somphot Fund, the Faculty of Medicine, Chulalong….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2014, the Expanded Program on Immunization of Thailand changed the timing of the second dose of the measles–mumps–rubella (MMR) vaccine from 4–6 years to 2.5 years, while maintaining the first dose at 9 months of age. This study aimed to examine the dynamics and durability of immune responses induced by the two-dose MMR vaccine in a group of 169 Thai children from 4 to 7 years of age (4.5 years after the second MMR dose). We followed a cohort of healthy children from a clinical trial (ClinicalTrials.gov NCT02408926) where they were administered either the Priorix vaccine (GlaxoSmithKline Biologicals, Rixensart, Belgium) or M-M-RII (Merck & Co., Kenilworth, NJ, USA) at 9 months and 2.5 years of age. Blood samples were collected annually from ages 4 to 7 years. Anti-measles, -mumps, and -rubella IgG levels were evaluated using the enzyme-linked immunosorbent assay (EUROIMMUN, Lubeck, Germany). A total of 169 children completed this study. Over the 4.5 years following the two-dose MMR vaccination, we observed a decline in the seroprotection rates against measles and mumps, but not rubella. Longitudinal monitoring of antibody persistence, among other strategies, will help predict population-level immunity and inform public health interventions to address potential future outbreaks.

Schlagwörter

Stichwörter der Autor:innen

antibodychildrenmeaslesmumpspersistencerubella

Autor:innen und Institutionen

  • Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
  • The Royal Society of Thailand, Dusit, Bangkok 10300, Thailand.

ORCID-Profile: Nasiri Sarawanangkoor, Nasamon Wanlapakorn, Yong Poovorawan

Förderung

  • National Research Council of Thailand (NRCT)
  • the Health Systems Research Institute (HSRI)
  • National Research Council of Thailand (NRCT), the Health Systems Research Institute (HSRI), the Ratchadaphisek Somphot Fund, the Faculty of Medicine, Chulalong…
  • Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University

Zitieren

APA

Sarawanangkoor, N., Wanlapakorn, N., Srimuan, D., Thatsanathorn, T., Thongmee, T., & Poovorawan, Y. (2024). Persistence of Antibodies against Measles, Mumps, and Rubella after the Two-Dose MMR Vaccination: A 7-Year Follow-Up Study. Vaccines, 12(7), 744. https://doi.org/10.3390/vaccines12070744

Vancouver

Sarawanangkoor N, Wanlapakorn N, Srimuan D, Thatsanathorn T, Thongmee T, Poovorawan Y. Persistence of Antibodies against Measles, Mumps, and Rubella after the Two-Dose MMR Vaccination: A 7-Year Follow-Up Study. Vaccines. 2024;12(7):744. doi:10.3390/vaccines12070744

BibTeX
@article{Sarawanangkoor2024,
  author = {Sarawanangkoor, Nasiri and Wanlapakorn, Nasamon and Srimuan, Donchida and Thatsanathorn, Thaksaporn and Thongmee, Thanunrat and Poovorawan, Yong},
  title = {Persistence of Antibodies against Measles, Mumps, and Rubella after the Two-Dose MMR Vaccination: A 7-Year Follow-Up Study},
  journal = {Vaccines},
  year = {2024},
  volume = {12},
  number = {7},
  pages = {744},
  doi = {10.3390/vaccines12070744}
}
Kostenlos starten →